|
|
Before anyone made money treating obesity some industries were making money from it. |
|
One Number
The size of the US weight-loss industry in 2025. Marketdata This is the market obesity created that grew for decades not by solving the problem but by managing it. Yet a rival market is now large enough to swallow it — anti-obesity drug sales are on track to grow from $19.6 billion in 2025 to $104.9 billion by 2035. |
|
One Argument Four industries - food, apparel, airlines and fitness - each had a settled position in the obesity economy. GLP-1 is now forcing every one of them to change.Every failed attempt to keep weight off was structurally good for some businesses. Diet chains, clinics, bariatric surgery (stomach-reduction operations for severe obesity), they all needed the problem to persist to keep growing. The medical weight-loss segment alone amounted to $21 billion, says Marketdata, with bariatric surgery peaking at above 230,000 procedures a year, according to American Society for Metabolic and Bariatric Surgery. Today commercial diet chain revenue is down 25%, with 26,500 coaches already out of work, according to Marketdata. JPMorgan estimates that $30-55 billon of food and beverage sales will be at risk by 2030. Airlines paid for obesity without ever pricing it in. The industry now expects $580 million in annual fuel savings from GLP-1 adoption, according to Jefferies forecast. Apparel and fitness break the pattern. GLP-1 is adding up to $13 billion in new US apparel spend as whole wardrobes get replaced after weight-loss, according to Bernstein. This is demand that didn’t exist before. The gym and studio market is projected to grow $6.8 billion, according to Harrison Co., even as bariatric surgery volume falls 23% from its 2022 peak, as ASMBS says. Airlines and half of fitness are recovering value obesity took from them, while apparel and the other half of fitness are capturing value that never existed before. A BMJ study in January 2026 found that patients who stop GLP-1 injections regain weight four times faster than those who stop conventional dieting. Today’s “winners” are thus exposed to the same reversal risk in case adoption plateaus or affordability stalls. But that exposure isn't evenly distributed: airlines and gyms are betting on adoption holding steady, while apparel's spend — once a wardrobe is replaced — has already happened and can't be clawed back the same way.
|
|
One Position Apparel is the only reversal built to last, because it doesn't require the patient to stay on the drug. For anyone with exposure to airline or gym equities on a GLP-1 thesis, the real question isn't adoption growth — it's retention. That's a very different due-diligence question than the one most people are asking. I may be wrong if extended and plus-size apparel demand rebounds. Discontinued GLP-1 users regaining weight four times faster than dieters is the mechanism that would prove it wrong. Which of these four bets are you personally exposed to — and did you check whether it depends on people staying on the injection, or on the weight loss itself? |
|
If this was forwarded to you and you'd like to receive Corporate Financier's Notes every Thursday, you can subscribe here. Reading on your phone? Tap the three dots or overflow menu in the top corner of your email app and select View in browser for the best experience.
|